« Zurück
Home /
Hexamethylene bisacetamide

Hexamethylene bisacetamide

ArtNr	HY-124284-100mg
Hersteller	MedChem Express
CAS-Nr.	3073-59-4
Menge	100 mg
Quantity options	100 mg 10 mM/1 mL 1 ea 200 mg 25 mg 50 mg
Kategorie	Reagents & Chemicals Biochemicals
Typ	Chemicals
Specific against	other
Purity	99.56
Citations	[1]Li XN, et al. Modulation effects of hexamethylene bisacetamide on growth and differentiation of cultured human malignant glioma cells. J Neurosurg. 1996 May;84(5):831-8. [2]Dey A, et al. Hexamethylene bisacetamide (HMBA) simultaneously targets AKT and MAPK pathway and represses NF kappaB activity: implications for cancer therapy. Cell Cycle. 2008 Dec;7(23):3759-67. [3]Cecchinato V, et al. Hexamethylene bisacetamide inhibits malignant phenotype in T-ALL cell lines. Leuk Res. 2008 May;32(5):791-7. https://pubmed.ncbi.nlm.nih.gov/17964649/ [4]Nilsson LM, et al. Muralidharan SV, Demir D, Welin M, Bhadury J, Logan DT, Walse B, Nilsson JA. Cancer Differentiating Agent Hexamethylene Bisacetamide Inhibits BET Bromodomain Proteins. Cancer Res. 2016 Apr 15;76(8):2376-83. [5]Park S, et al. HMBA ameliorates obesity by MYH9- and ACTG1-dependent regulation of hypothalamic neuropeptides. EMBO Mol Med. 2023 Dec 7;15(12):e18024.
Smiles	CC(NCCCCCCNC(C)=O)=O
ECLASS 10.1	32160000
ECLASS 11.0	32160000
UNSPSC	12000000
Alias	HMBA
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Akt; Apoptosis; Bcl-2 Family; Epigenetic Reader Domain; MDM-2/p53; NF-κB; Notch; p38 MAPK
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, protect from light)
Molecular Weight	200.28
Product Description	Hexamethylene bisacetamide (HMBA) is a differentiation inducer and selective bromine domain inhibitor that can differentiate across the blood-brain barrier. Hexamethylene bisacetamide can induce tumor cell differentiation and inhibit cell proliferation, showing antitumor activity. Hexamethylene bisacetamide induces apoptosis by Notch1, Bcl-2 and p53 signaling pathways. In addition, Hexamethylene bisacetamide improves the obesity phenotype of mice[1][2][3][4][5].
Manufacturer - Research Area	Cancer; Metabolic Disease; Neurological Disease
Solubility	DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)\|H2O : 100 mg/mL (ultrasonic)
Manufacturer - Pathway	Apoptosis; Epigenetics; MAPK/ERK Pathway; Neuronal Signaling; NF-κB; PI3K/Akt/mTOR; Stem Cell/Wnt
Clinical information	No Development Reported

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkdatenblatt anfordern

HY-124284-100mg-safety-datasheet.pdf